74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Harmony Biosciences Holdings Inc
Closed
SectorHealthcare
29.26 1.25
Overview
Share price change
24h
Min
28
Max
29.45
Income | 3.4M 49M |
|---|---|
Sales | 15M 201M |
P/E Sector Avg | 11.355 57.333 |
EPS | 1.08 |
Profit margin | 24.582 |
Employees | 268 |
EBITDA | -6.2M 66M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +84.58% upside |
Next Earnings | 29 Apr 2025 |
|---|
Market Cap | -314M 1.6B |
|---|---|
Previous open | 28.01 |
Previous close | 29.26 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Harmony Biosciences Holdings Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Harmony Biosciences Holdings Inc Forecast
Price Target
By TipRanks
84.58% upside
12 Months Forecast
Average 53.86 USD 84.58%
High 70 USD
Low 32 USD
Based on 8 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
